Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT03439046 | Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on…(BioItaLEE) | Phase 3 | terminated | Feb 20, 2018 | Novartis Pharmaceuticals | Novartis terminated the trial early because the collected data were sufficient to perform the… | Other (stated, no rule matched) |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | Phase 1 / Phase 2 | withdrawn | Apr 16, 2020 | Chongqing Precision Biotech Co., Ltd | The sponsor requested to terminate the study. | Other (stated, no rule matched) |
| NCT03946423 | BAriaTric Surgery After Breast Cancer Treatment (BATS) | N/A | withdrawn | May 10, 2019 | Masonic Cancer Center, University of Minnesota | Not moving forward with study. | Other (stated, no rule matched) |
| NCT04331067 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast… | Phase 1 / Phase 2 | terminated | Apr 2, 2020 | Washington University School of Medicine | BMS terminated the study | Other (stated, no rule matched) |
| NCT07693374 | Chinese Medicinal Component Relieves CIPN and Mitochondria Function | N/A | withdrawn | Jul 9, 2026 | Taiwan Municipal An-Nan Hospital-China Medical University | Initial prep showed that formulation, QC, and cost for high-dose paeonol/Cortex Moutan exceeded the… | Safety / toxicity |
| NCT04216472 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple… | Phase 2 | terminated | Jan 2, 2020 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04273555 | Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients… | Phase 1 / Phase 2 | withdrawn | Feb 18, 2020 | University of Alabama at Birmingham | Unable to recruit for this study. | Enrollment / accrual |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT05207709 | Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the…(HARMONIA) | Phase 3 | terminated | Jan 26, 2022 | SOLTI Breast Cancer Research Group | The study was prematurely halted because enrollment was significantly delayed compared with the… | Enrollment / accrual |
| NCT07136493 | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With… | N/A | withdrawn | Aug 22, 2025 | City of Hope Medical Center | Funding This study has been closed at City of Hope at the request of the Sponsor due to delays and… | Funding |
| NCT00520975 | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses… | Phase 3 | terminated | Aug 27, 2007 | National Cancer Institute (NCI) | Closed early due to slow accrual | Enrollment / accrual |
| NCT05315011 | Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia(CRYOMATASE) | N/A | suspended | Apr 7, 2022 | University Hospital, Montpellier | The cryotherapy center has closed due to liquidation. | Other (stated, no rule matched) |
| NCT05350527 | Impact of Video Information Support on Preoperative Anxiety in Breast Cancer Surgery(SENEDOP) | N/A | terminated | Apr 28, 2022 | University Hospital, Montpellier | The software used for the collection of the primary endpoint is no longer available. | Other (stated, no rule matched) |
| NCT00253318 | RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer | Phase 1 | terminated | Nov 15, 2005 | M.D. Anderson Cancer Center | Toxicity and Lack of Efficacy | Safety / toxicity |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | terminated | Aug 24, 2022 | Day One Biopharmaceuticals, Inc. | Development discontinued. | Other (stated, no rule matched) |
| NCT03879629 | Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to… | Phase 2 | terminated | Mar 19, 2019 | Mayo Clinic | slow accrual; insufficient funding to continue to accrue | Enrollment / accrual |
| NCT02409316 | [18F]FES PET/CT in Endocrine Refractory Breast Cancer | Phase 2 | terminated | Apr 6, 2015 | University of Pennsylvania | not stated | Not stated |
| NCT04906369 | Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring | — | suspended | May 28, 2021 | Mayo Clinic | lack of funding | Funding |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT03674515 | Study of Program Interest "Bouge" to Improve the Daily Physical Activity in Processings…(BOUGE CANCER) | N/A | terminated | Sep 17, 2018 | University Hospital, Brest | not stated | Not stated |
| NCT06214793 | Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) | Phase 2 | suspended | Jan 22, 2024 | Megan Kruse, MD | Anheart acquired by Nuvation Bio; leadership not moving forward | Other (stated, no rule matched) |
| NCT03632941 | A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With… | Phase 2 | terminated | Aug 16, 2018 | Herbert Lyerly | Enrollment issue | Enrollment / accrual |
| NCT05183828 | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | Phase 4 | terminated | Jan 11, 2022 | University of Washington | Study ended earlier than anticipated due to end of funding. | Funding |
| NCT06351332 | ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC | Phase 1 | terminated | Apr 8, 2024 | Filipa Lynce, MD | Zentalis terminated contract due to concern for toxicity safety from previously reported serious… | Safety / toxicity |
| NCT04168528 | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | Phase 1 / Phase 2 | terminated | Nov 19, 2019 | Universitair Ziekenhuis Brussel | Delay in recruitment | Enrollment / accrual |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk… | Other (stated, no rule matched) |
| NCT03199885 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive… | Phase 3 | terminated | Jun 27, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04016818 | Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution | Early Phase 1 | withdrawn | Jul 12, 2019 | Stanford University | Awaiting more funding to build a more stable technology. | Funding |
| NCT06878248 | A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast… | Phase 1 | terminated | Mar 14, 2025 | Calibr, a division of Scripps Research | Business Decision | Sponsor / business decision |
| NCT03765983 | GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer… | Phase 2 | terminated | Dec 5, 2018 | Dana-Farber Cancer Institute | participants are no longer being examined or receiving intervention | Other (stated, no rule matched) |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to… | Phase 3 | terminated | Oct 19, 2020 | NRG Oncology | Inadequate accrual rate | Enrollment / accrual |
| NCT05368428 | Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy… | N/A | terminated | May 10, 2022 | Emory University | PI Decision | Other (stated, no rule matched) |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT05085002 | A Study of Lerociclib in Participants With Advanced Breast Cancer | Phase 2 | terminated | Oct 20, 2021 | EQRx, Inc. | The study is being closed based on corporate changes at EQRx and is not related to any efficacy or… | Safety / toxicity |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT06844669 | HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving… | Phase 2 | terminated | Feb 25, 2025 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT04541381 | The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care | N/A | suspended | Sep 9, 2020 | University of Chicago | pending study amendment/re-design | Other (stated, no rule matched) |
| NCT05452681 | Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast… | N/A | terminated | Jul 11, 2022 | University of Alabama at Birmingham | The recruitment for the study slowed and funding for the study has completed. | Enrollment / accrual |
| NCT02664389 | Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in…(PANEL) | N/A | terminated | Jan 27, 2016 | University Hospital, Rouen | Difficulty in enrolling patients | Enrollment / accrual |
| NCT06617455 | Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking…(VEnT) | Phase 2 | terminated | Sep 27, 2024 | University of Michigan Rogel Cancer Center | Lack of Patient Interest | Other (stated, no rule matched) |
| NCT03838419 | Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer(COSMOPOLITAN) | N/A | suspended | Feb 12, 2019 | University Hospital Heidelberg | Organizational reasons | Other (stated, no rule matched) |
| NCT04370522 | Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer(NIKOLE) | — | terminated | May 1, 2020 | Spanish Breast Cancer Research Group | Lack of funding to continue the research into Phase II | Funding |
| NCT03738553 | Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy | — | terminated | Nov 13, 2018 | University of Washington | Study closed to accrual after meeting grant enrollment goal, prior to reaching protocol accrual… | Enrollment / accrual |
| NCT05755269 | Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African… | — | terminated | Mar 6, 2023 | Mayo Clinic | Lack of funding | Funding |
| NCT07134556 | Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab,…(ADJUNCT) | Phase 2 | withdrawn | Aug 21, 2025 | MedSIR | The interim analysis of the STAR-221 study showed that the domvanalimab combination did not improve… | Safety / toxicity |
| NCT06456411 | Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain… | N/A | terminated | Jun 13, 2024 | Roswell Park Cancer Institute | PI left | Investigator |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT01472445 | Vitamin D and Breast Cancer: Does Weight Make a Difference? | Phase 2 | terminated | Nov 16, 2011 | Melinda Telli | Slow accrual | Enrollment / accrual |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or… | Phase 2 | terminated | Aug 22, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | study closed early due to slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 13, 2026source: clinicaltrials